SCYNEXIS, Inc. (Nasdaq:SCYX) to Ring The NASDAQ Stock Market Closing Bell

By GlobeNewswire,  June 27, 2014, 10:00:00 AM EDT

SCYNEXIS, Inc. (Nasdaq:SCYX) to Ring The NASDAQ Stock Market Closing Bell


ADVISORY, June 27, 2014 (GLOBE NEWSWIRE) --

What:

SCYNEXIS, Inc. (Nasdaq:SCYX), a drug discovery and development company, will visit the NASDAQ MarketSite in Times Square to commemorate the successful closing of its initial public offering.

In honor of the occasion, Yves J. Ribeill, Ph.D., SCYNEXIS' President and Chief Executive Officer, will ring the Closing Bell.

Where:

NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio

When:

Monday, June 30, 2014 - 3:45 p.m. to 4:00 p.m. ET       

SCYNEXIS, Inc. Contact:

Heather Savelle

(781) 235-3060

hsavelle@macbiocom.com

NASDAQ MarketSite:

Christine Barna

(646) 441-5310

Christine.Barna@nasdaqomx.com

Feed Information:

Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West

18 mhz Lower

DL 3811 Vertical

FEC 3/4

SR 13.235

DR 18.295411

MOD 4:2:0

DVBS QPSK

Social Media:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ.

For photos from ceremonies and events visit our Instagram Page:http://instagram.com/nasdaq.

For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx.

For exciting viral content and ceremony photos visit Tumblr Page: http://nasdaq.tumblr.com/.

Webcast:

A webcast of the NASDAQ Closing Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx.

Photos:

To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.

About SCYNEXIS, Inc.(Nasdaq:SCYX):

SCYNEXIS is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. For more information, visit www.scynexis.com.

About NASDAQ OMX Group

NASDAQ OMX (Nasdaq:NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, NASDAQ OMX enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. NASDAQ OMX is home to more than 3,400 listed companies with a market value of over $8.5 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaqomx.com.

-NDAQA-

Source: The NASDAQ OMX Group, Inc.

This article appears in: News Headlines

Referenced Stocks: NDAQ, SCYX


Latest News Video





Most Active by Volume

Company Last Sale Change Net / %
BAC $ 16.16 0.64 ▲ 4.12%
EBAY $ 55.89 2.49 ▲ 4.66%
HPQ $ 37 1.88 ▲ 5.35%
INTC $ 35.15 0.65 ▲ 1.88%
JRJC $ 9.74 0.57 ▲ 6.22%
AAPL $ 100.58 0.01 ▲ 0.01%
HTZ $ 30.10 0.23 ▼ 0.76%
NOK $ 8.25 0.12 ▲ 1.48%

As of 8/21/2014, 04:03 PM